pp-104 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Type 2 diabetes mellitus in adult patients, targeting improved glycemic control in combination therapy settings
Clinical stage: Early clinical development — Phase 1 safety and pharmacokinetic evaluation in healthy volunteers and patients
Modality: Small molecule (oral antidiabetic agent)
Mechanism / Target: Designed as a multi‑component metabolic agent to modulate glucose metabolism pathways and improve glycemic outcomes
Route / form: Oral tablet (fixed‑dose combination)
Differentiation: Investigated as a fixed‑dose combination antidiabetic therapy aimed at enhancing efficacy and convenience relative to separate agents
Manufacturer #11806
Clinical-stage biopharma focused on autoimmune and inflammatory diseases. Pipeline emphasizes selective oral small molecules with improved safety profiles. Active in global development and strategic partnerships.